Chicago-based Sibel Health, a medical technology company, has been picked by the capital region of Denmark for a long-term partnership in conjunction with Dräger, a medical safety technology company, to deploy advanced continuous monitoring in the hospital setting.

Sibel Health's FDA-cleared ANNE One platform contains advanced wearable sensors, AI-enabled data analytics and an integrated mobile software and cloud platform. 

The capital region of Denmark is in need of new monitoring technologies to deal with staffing shortages, an increase in patient load and the move to single rooms in its hospitals, the companies said in a statement.

Following a collaborative joint innovation phase, Sibel's platform will be deployed in multiple Copenhagen area hospitals.

The collaboration will ultimately include a four-year purchase agreement and installation in more than 1,000 hospital beds at a total estimated purchase value greater than $20 million (141 million DKK). 

The Sibel platform is also expected to be used in other Danish regions beyond the capital region over a 10-year period at a total estimated purchase value in excess of $100 million (706 million DKK). 

"We are deeply honored for Sibel Health and our ANNE One monitoring platform with advanced medical wearables to be selected by the Capital Region of Denmark," Dr. Steve Xu, CEO and cofounder of Sibel Health, said in a statement.

"The future of monitoring centers on technology that surveils a patient's condition wirelessly and continuously, reduces physical and cognitive load for nurses, and seamlessly integrates with hospital IT infrastructure. We look forward to ensuring the solution fits the needs of the Capital Region of Denmark perfectly." 

THE LARGER TREND

In 2023, Sibel Health released its physiological monitoring platform for clinical trial use dubbed Discovery, alongside a partnership with AI-powered clinical trial-solutions company Medidata. 

That same year, Sibel Health received FDA 510(k) clearance for its ANNE One platform to include continuous neonate and vital-sign monitoring of infants born at any gestational age up to two years old. The platform previously received FDA clearance for vital-sign monitoring for adults in healthcare settings for clinical decision-making. 

In 2022, Sibel Health scored $33 million in a Series B funding round led by the Steele Foundation for Hope. The company used the funds to deploy its ANNE One platform for in-home and hospital monitoring.